
Please try another search
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Name | Age | Since | Title |
---|---|---|---|
Magda Marquet | 63 | 2021 | Independent Director |
Jane Melissa Buchan | 58 | 2021 | Independent Director |
Ilya Rachman | 50 | 2012 | Co-Founder, CEO & Chairman |
Helen C. Adams | 64 | 2021 | Lead Independent Director |
Gary J. Schiller | - | - | Member of Scientific Advisory Board |
Carey J. Ng | 46 | 2019 | Independent Director |
Jason Hsu | 50 | 2013 | Independent Director |
Suzanne Lentzsch | - | 2023 | Member of Scientific Advisory Board |
Vaishali Sanchorawala | - | - | Member of Scientific Advisory Board |
Marko Radic | - | 2023 | Member of Scientific Advisory Board |
Yekaterina Chudnovsky | 40 | 2023 | Independent Director |
Heather Landau | - | 2023 | Member of Scientific Advisory Board |
Michaela Liedtke | - | 2023 | Member of Scientific Advisory Board |
Gabriel Morris | 38 | 2021 | CFO & Director |
Raymond Comenzo | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review